In a new analysis of genetic susceptibility to kidney cancer, an international team of researchers has identified 50 new areas across the genome that are associated with the risk of developing kidney cancer. These insights ...
41 minutes ago
0
0
Researchers from The University of Texas MD Anderson Cancer Center presented encouraging findings from two clinical trials in a plenary session highlighting advances in novel immunotherapy approaches at the American Association ...
Apr 8, 2024
0
0
Scientists have developed a new AI tool that maps the function of proteins in a cancerous tumor, enabling clinicians to decide how to target treatment in a more precise way.
Feb 9, 2024
0
28
For patients with clear-cell renal cell carcinoma (ccRCC), overall survival (OS) is improved for those receiving pembrolizumab versus placebo at a median follow-up of about 57 months, according to a study presented at the ...
Feb 1, 2024
0
1
Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen in the results of a large ...
Jan 29, 2024
0
0
About 100 cancer predisposition genes (CPGs) are known. The probability of developing cancer is greater in individuals who inherit certain altered variants of one of these genes.
Jan 16, 2024
0
0
Immune checkpoint inhibitors (ICIs) are used to treat a variety of different cancers. ICIs are antibodies that sensitize the body's own immune system to detect and destroy tumors. However, ICIs are not effective in all patients, ...
Jan 3, 2024
0
50
It's no secret that a high-fiber diet is good for you—just ask Google. Lots of research suggests that eating a high-fiber diet can lower your risk for certain cancers, but less is known about whether fiber can also help ...
Dec 13, 2023
0
0
A new study, published online ahead of print in Journal for ImmunoTherapy of Cancer on December 6, has identified a novel biomarker for ICIs in human cancers.
Dec 13, 2023
0
12
A study by the University of the Basque Country (UPV/EHU) uses game theory to establish that tumors with less cellular heterogeneity are more aggressive
Dec 4, 2023
0
0
Renal cell carcinoma (RCC, also known as hypernephroma) is a kidney cancer that originates in the lining of the proximal convoluted tubule, the very small tubes in the kidney that filter the blood and remove waste products. RCC is the most common type of kidney cancer in adults, responsible for approximately 80% of cases. It is also known to be the most lethal of all the genitourinary tumors.[citation needed] Initial treatment is most commonly a radical or partial nephrectomy and remains the mainstay of curative treatment. Where the tumor is confined to the renal parenchyma, the 5-year survival rate is 60-70%, but this is lowered considerably where metastases have spread. It is relatively resistant to radiation therapy and chemotherapy, although some cases respond to immunotherapy. Targeted cancer therapies such as sunitinib, temsirolimus, bevacizumab, interferon-alpha, and sorafenib have improved the outlook for RCC (progression-free survival), although they have not yet demonstrated improved survival.
This text uses material from Wikipedia licensed under CC BY-SA
